Select Page
Responsive Centered YouTube Video
Analysis of potential outcomes of mass vaccination program against SARS-COV2 virus
  • Dr. Philip McMillan discusses Gert Vanden Bossche’s predictions on SARS-COV2 virus reaction to mass vaccination. 0:01

  • No guarantee on accuracy of predictions, but considering all possibilities is crucial for risk management. 0:21

  • Gert’s accurate predictions in the past raise concerns about potential worst outcomes. 0:46

  • Gert warns about poor neutralizing capacity in vaccinated populations leading to spread of highly infectious variants. 1:28

  • Emphasis on prospective analysis based on understanding virus-host interplay rather than standard modeling. 3:05

Impact of mass vaccination on virus evolution and spread of more infectious variants
  • Increasing immune pressure from mass vaccination favors more infectious variants. 3:57

  • Higher vaccine coverage rates lead to dominance of more infectious variants. 4:03

  • More infectious variants like Omicron may have an advantage due to immune pressure. 4:34

  • Omicron increases infectiousness by evading neutralizing antibodies. 4:59

  • Vaccinated individuals may have poor neutralizing capacity against Omicron. 6:04

  • Diminished neutralizing capacity results in higher infection-enhancing antibodies. 7:08

Impact of Omicron variant on viral characteristics and vaccine response
  • Omicron may have the advantage of spreading further due to non-neutralizing antibodies enhancing infection. 7:26

  • Scientific community debates on the term ‘antibody dependent enhancement of infection’ in relation to Omicron. 7:45

  • Omicron is perceived as less virulent and may lead to decreased shedding of the virus by vaccinated individuals. 8:46

  • Increased infectiousness, decreased virulence, and shedding patterns are observed with Omicron. 9:25

  • Resistance to neutralizing antibodies may inhibit trans infection and viral replication on dendritic cells. 10:51

Implications of low neutralizing antibodies on SARS-COV2 viral spread and virulence
  • Paper discusses how lectins enhance SARS-CoV-2 infection in cells with low ACE2 levels. 11:37

  • Virus can spread from cell to cell without using ACE2 in cells with low ACE2 levels. 12:20

  • Neutralizing antibodies may increase infectiousness in upper respiratory tract. 13:04

  • Antibodies predicted to promote cell-to-cell spread in lower respiratory tract, potentially increasing virulence. 13:32

  • Poor neutralizing capacity could lead to super variants with high infectivity and virulence. 14:35

  • Current phase shows high infectiousness but not high virulence, potential for change with viral evolution. 15:02

Contingency planning for high infection and virulence scenarios in COVID-19 pandemic
  • Reflecting on risk management in pandemic situations 15:30

  • Acknowledging expertise of Gert in the field 15:39

  • Creating contingency plans for worst-case scenarios 16:07

  • Strategizing to reduce risk of increased mortality in COVID-19 16:23

  • Sharing Gert’s recommendations and personal ideas 16:32

  • Inviting audience to join the journey on Substack for more information 16:49

  • Emphasizing the ongoing work and questions in understanding COVID-19 17:05